Astria Therapeutics in the spotlight (part II)
Analyzing $ATXS data and upside relative to F-Star Therapeutics, while comparing to Takeda and BioCryst options
Astria Therapeutics (ATXS) announced the FDA clearance of their IND application for STAR-0215 for hereditary angioedema (HAE). A Phase 1a trial of STAR-0215 in healthy volunteers is expected to initiate in the coming weeks, with preliminary results anticipated by year-end 2022.
The Phase 1a trial is planned to be a randomized, double-blind, placebo-cont…